Serum adipocyte-type fatty acid binding protein and interleukin-17 levels in patients with type 2 diabetes mellitus and their relationship with lower limb atherosclerosis
WANG Lu1 BAI Hua1 HAN Mei1 ZHAO Yuyan2
1.Department of Endocrinology, Jinqiu Hospital of Liaoning, Liaoning Province, Shenyang 110016, China;
2.Department of Endocrinology, the First Affiliated Hospital, Chinese Medical University of Liaoning, Liaoning Province, Shenyang 110001, China
Abstract:Objective To investigate the relationship between serum adipocyte-type fatty acid binding protein (A-FABP) and interleukin-17 (IL-17) expression levels and lower limb atherosclerosis (LEAD) in patients with type 2 diabetes. Methods A total of 131 patients with type 2 diabetes admitted to Jinqiu Hospital of Liaoning Province (hereinafter referred to as "our hospital") from February 2017 to November 2017 were divided into non-lead group (n = 34) and non-lead group (n = 97) according to ankle-brakle index (ABI), and 45 healthy subjects in our hospital were randomly selected as the control group during the same period. Serum levels of A-FABP and IL-17 were determined by enzyme-linked immunosorbent assay, and the influencing factors of LEAD in type 2 diabetes were analyzed by Logistic regression. ROC curve was used to evaluate the predictive value of A-FABP and IL-17 on LEAD. Results The duration of diabetes in the LEAD group was longer than that in the non-lead group (P < 0.05). The systolic blood pressure, glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), low-density lipoprotein cholesterol (LDL-C), serum creatinine (SCr), A-FABP, and IL-17 levels in the LEAD group and the non-lead group were higher than those in the control group (P < 0.05). Multivariate Logistic regression analysis showed that LDL-C, A-FABP and IL-17 were independent risk factors of LEAD in type 2 diabetes (OR = 1.418, 1.657, 1.619, P < 0.05). The area under the curve (AUC) of A-FABP combined with IL-17 was 0.906, the sensitivity and specificity were 0.89 and 0.86, respectively, and the accuracy was 0.90. Conclusion Serum A-FABP and IL-17 are independent risk factors of LEAD in patients with type 2 diabetes. Early combined detection is helpful to predict LEAD in the early clinical stage, so as to guide clinical development of early intervention measures.
王露1 白桦1 韩梅1 赵玉岩2. 2型糖尿病患者血清脂肪细胞型脂肪酸结合蛋白、白细胞介素-17水平及其与下肢动脉粥样硬化病变的关系[J]. 中国医药导报, 2019, 16(8): 116-119,135.
WANG Lu1 BAI Hua1 HAN Mei1 ZHAO Yuyan2. Serum adipocyte-type fatty acid binding protein and interleukin-17 levels in patients with type 2 diabetes mellitus and their relationship with lower limb atherosclerosis. 中国医药导报, 2019, 16(8): 116-119,135.